MUMBAI, India, June 6 -- Intellectual Property India has published a patent application (202517037674 A) filed by Neurocrine Biosciences, Inc., San Diego, on April 18, for 'hexahydro-2h-pyrido[2,1-a]isoquinoline vmat2 inhibitors and methods of use.'
Inventor(s) include Boon, Byron, A.; Pagano, Nicholas; Harriott, Nicole; Gu, Jieyu; and Xue, Yibin.
The application for the patent was published on June 6, under issue no. 23/2025.
According to the abstract released by the Intellectual Property India: "This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter-2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of the compounds."
The patent application was internationally filed on Sept. 20, 2023, under International application No.PCT/US2023/033206.
Disclaimer: Curated by HT Syndication.
